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ABSTRACT
In recent years, there have been worldwide efforts to reduce inappropriate antibiotic prescribing. This
has mainly been in response to mounting concerns about the emergence of antimicrobial resistance.
Surprisingly, there has been little systematic investigation of the impact of antibiotic restrictions on the
complications of infection. It is difﬁcult to address this question using randomised clinical trials in light
of the often limited numbers of patients that can be included, who are also often atypical of the broad
population of patients receiving antibiotic therapy. Observational data from the UK indicate an
association between recent reductions in antibiotic prescribing for lower respiratory tract infection in
general practice and an increase in pneumonia mortality. These studies suggest a need for further
investigations examining the changing patterns of antibiotic prescribing and their effects on patient
outcomes in other countries and in other common infectious diseases. Such studies may provide a useful
comparison with the changes observed in lower respiratory tract infection in the UK, and could help to
improve antibiotic prescribing practices worldwide. It is also important to study whether associated
worse outcomes are limited to certain at-risk groups who should be targeted for care.
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INTRODUCTION
For most of human history, infectious diseases
have exerted a substantial mortality burden. In
the developing world, nearly 55% of mortality is
still caused by communicable diseases, compared
with approximately 23% of mortality globally [1].
In the developed world, the introduction of public
vaccination programmes, improved hygiene and
better nutrition, as well as the widespread use of
antibiotics, have greatly reduced mortality due to
most infectious diseases. However, despite these
gains, community-acquired pneumonia and inﬂu-
enza still remain signiﬁcant causes of mortality.
For example, in the USA, pneumonia is the
seventh leading cause of death overall and this
pattern is seen elsewhere throughout the devel-
oped world [2].
Mortality from community-acquired pneu-
monia is inﬂuenced by a number of well-deﬁned
risk factors [3]. When multiple risk factors are
present, patients should be hospitalised and
therapy becomes more aggressive [4]. The mor-
tality rate in hospitalised community-acquired
pneumonia patients ranges from 10% to as high
as 40% in elderly patients with severe disease
[5–8].
The key pathogen in community-acquired
pneumonia is Streptococcus pneumoniae, which
was identiﬁed in 66% of cases in a meta-analysis
of 6866 patients with demonstrated bacterial
infection [7]. However, other bacterial pathogens
can cause community-acquired pneumonia, e.g.,
Haemophilus inﬂuenzae, Moraxella catarrhalis and
the ‘atypical’ pathogens Chlamydia pneumoniae,
Mycoplasma pneumoniae and Legionella spp., and
coinfection is possible. A nonbacterial aetiology is
also common in certain populations; 4–39% of
immunocompetent adults with clinically deﬁned
community-acquired pneumonia have evidence
of viral infection, primarily inﬂuenza [9]. Inﬂu-
enza and other viral infections can cause primary
viral pneumonia or lead to secondary bacterial
infection, reported as occurring in 26–77% of
hospitalised adults with community-acquired
pneumonia [9].
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Increases in the prevalence of antibiotic-resist-
ant community-acquired pneumonia pathogens,
particularly penicillin- and ⁄ or macrolide-resist-
ant pneumococci, have been observed in many
regions of the world, with the highest preva-
lences observed in the Far East, Southern Eur-
ope and North America [10]. The impact of
drug-resistant S. pneumoniae in community-ac-
quired pneumonia is debated. Penicillin resist-
ance appears to have an adverse effect on
outcomes, but there is little evidence that this
is due to a failure of b-lactam therapy [11,12]. In
contrast, failures of macrolide therapy due to
macrolide resistance in S. pneumoniae have been
reliably documented [11]. Although ﬂuoroqui-
nolone resistance in S. pneumoniae is relatively
uncommon, failures during levoﬂoxacin therapy
have been reported [13,14].
The concern is that without intervention aimed
at controlling antibiotic resistance, the effective-
ness of currently available antibiotic therapy will
be undermined. This has led to the institution of
policies that restrict the use of antibiotics, partic-
ularly in respiratory tract infection, in many
countries.
IMPACT OF ANTIBIOTIC THERAPY
ON PNEUMONIA
We have come to rely on antibiotics to provide a
level of health that we now take for granted, at
least in the developed world. We have generally
forgotten the high burden of morbidity and
mortality from infectious disease that, until very
recently, was accepted as part of life. It is
therefore worth examining the beneﬁts that anti-
biotic therapy has brought us.
In the preantibiotic era, community-acquired
pneumonia was often fatal; untreated lobar
pneumonia had a 30% mortality rate overall,
and this increased steeply with age. To my
knowledge, there is only one randomised and
placebo-controlled trial comparing mortality in
untreated pneumonia with antibiotic therapy,
published in 1938 [15]. It was conducted in
patients who today would be considered to
have severe disease, with 100 patients receiving
sulfonamides and 100 receiving best supportive
care only. Overall mortality in this study was
27.0% for untreated patients vs. 8.0% for
patients treated with sulfonamides. Mortality
increased to 50.0% in untreated patients ‡ 40
years old (n ¼ 32) vs. 19.4% in those receiving
antibiotic therapy (n ¼ 31) [15]. It is difﬁcult for
us now to imagine half of all patients over
40 years of age dying of pneumonia, even in the
case of severe disease.
Community-acquired pneumonia is still a seri-
ous disease with a relatively high mortality rate,
particularly in the elderly [2,8]. However, with
appropriate antibiotic therapy, only those patients
who fail to develop leukocytosis are at high risk
of mortality. Antibiotics have also changed the
nature of the disease; necrotising lung abscesses
are now rare and instead patients present with an
homogenous airspace consolidation in the lung.
Complications, such as pneumococcal native valve
endocarditis, are also extremely rare and deserve
speciﬁc comment in the medical literature [16].
Some infectious diseases, if undertreated with
antibiotics, may have relatively benign conse-
quences and a low rate of complications. How-
ever, for an infection such as community-
acquired pneumonia, in which antibiotics have
had a profound effect on morbidity and mor-
tality, their underuse will lead to an increase in
adverse outcomes. Lower respiratory tract infec-
tion is difﬁcult to differentiate reliably from
community-acquired pneumonia in primary
practice, and may also lead to community-
acquired pneumonia if left untreated. As a
consequence, any clinically relevant changes in
prescribing trends across the spectrum of lower
respiratory tract infection are likely to affect
outcomes for pneumonia.
Despite these limitations in diagnosis, and the
potential seriousness of the infection, measures to
restrict antibiotic prescribing in lower respiratory
tract infection have been introduced in many
developed countries. Such measures aim to
reduce the antibiotic load in the hope of reducing
the emergence and spread of antibiotic-resistant
bacterial strains. Unfortunately, such control
measures, which may be enacted at many differ-
ent levels throughout the healthcare system, are
almost universally introduced without provision
for determining their impact on patient outcomes
or the implications of not treating patients with
lower respiratory tract infection or, in fact, anti-
biotic resistance – the very outcome that they aim
to modify. In addition, no clear evidence is
available to deﬁne what represents a clinically
relevant change in prescribing and the point at
which patients’ outcomes may be compromised.
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APPROACHES TO OUTCOMES
RESEARCH
How can we determine the impact of antibiotic
prescribing changes on patient outcomes in lower
respiratory tract infection? Randomised con-
trolled trials are often quoted as the ‘standard’
evidence upon which to base clinical decisions. It
is certainly true that, when conducted properly,
they offer a reliable method of comparing two
interventions in a well-deﬁned patient population.
The major difﬁculty that we have in primary care
is that our patient population is not ‘well deﬁned’,
but extremely heterogeneous. For example, in the
case of lower respiratory tract infections, we see
the whole age spectrum, and patients with any
and multiple comorbidities, who are from diverse
social ⁄ economic backgrounds.
Randomised clinical trials are often powered to
show noninferiority of one treatment to an estab-
lished therapy. The reason for this is that a large
number of patients are required to determine
superiority of one intervention over another
which is, of course, expensive. Unfortunately, this
approach is insensitive to small changes in out-
come between interventions and the type of
intervention that can be studied is also limited.
An additional issue in the case of community-
acquired pneumonia is that it would be unethical
to enrol patients suspected of having this infec-
tion and not treat them with antibiotics. Thus,
although randomised clinical trials can answer
very speciﬁc questions, and can raise issues for
further research, they are inadequate in isolation
for looking critically at interventions in the dis-
eases and conditions that we see commonly in the
primary care setting. In particular, investigating
the effect of changes in the frequency of antibiotic
prescribing for lower respiratory tract infection on
outcomes for community-acquired pneumonia
would be problematic ethically and practically,
and it is unlikely that the results could be
generalised to the wider patient population.
We must therefore look for alternative, epi-
demiology-based methods of investigation, e.g.,
case–control studies, cohort studies and data
mining of epidemiological databases. These ‘qua-
si-experiments of opportunity’ are often criticised
for being less rigorous than randomised con-
trolled trials. However, when the ﬁndings of
observational studies have been compared with
those of randomised controlled trials, their sensi-
tivity for measuring outcomes has been found to
be at least as good [17,18]. For example, in a meta-
analysis of randomised, controlled trials, or
cohort or case–control studies assessing the same
intervention in ﬁve clinical areas, there was a high
degree of concordance in the results obtained
using the different research methods [18]. In fact,
comparison of 13 randomised, controlled trials of
the effectiveness of bacille Calmette–Gue´rin vac-
cine in preventing active tuberculosis with data
from ten case–control studies revealed that the
point estimates for the effect of vaccination were
wider for the randomised, controlled trials than
for the observational studies [18]. As for all
clinical studies, of any design, some are well
conducted and others less so. However, it seems
that there is no reason why well-designed obser-
vational studies should not provide evidence that
is at least as valid as that obtained from a well-
designed randomised controlled trial. In addition,
where the results of randomised trials and obser-
vational studies are discordant, useful informa-
tion can be obtained by further investigating the
reasons for differences in the conclusions, rather
than assuming that the observational studies are
ﬂawed.
RESPONSE TO ANTIBIOTIC
RESISTANCE IN THE UK
In the early 1990s the prevalence of antibiotic-
resistant respiratory tract pathogens in the UK
was among the lowest in Europe. However, from
c. 1996, data suggested that the prevalence of
penicillin-resistant and macrolide-resistant
S. pneumoniae was increasing [19]. Surveillance
data for 1998–2000 conﬁrmed that resistance was
emerging in the UK with 84% of S. pneumoniae
strains isolated from respiratory tract infections
susceptible to penicillin and 87% susceptible to
erythromycin, although the situation was still
much better than in France where only 42% and
47% of strains were susceptible to these antibiot-
ics, respectively [10].
The increasing prevalence of antibiotic resist-
ance in the UK, particularly in pneumococci,
engendered considerable efforts to attempt to
stabilise or reverse this trend, mostly focused on
the control of antibiotic prescribing. Table 1
outlines some of the major initiatives aimed at
reducing antibiotic resistance taken between
1998 and 2001.
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The earliest of these initiatives, in March 1998,
was a report entitled Resistance to Antibiotics and
other Antimicrobial Agents commissioned by the
House of Lords Select Committee on Science and
Technology [20]. At this time, compared with
some other European countries, antibiotic pre-
scribing was already strictly regulated in the UK,
with systemic antibiotics only available upon
prescription from a doctor, dentist or veterinary
surgeon (not from a nurse prescriber). The
Association of Medical Microbiologists stated that
c. 80% of antibiotic prescribing in UK general
practice was ‘fully justiﬁed’; this was across all
indications, not just in lower respiratory tract
infection. This group also cautioned that ‘The
continuing legitimate use of antibiotics in humans
may still sustain and might even increase the
amount of resistance’, reﬂecting the reality that,
with any antibiotic use, bacterial resistance is
inevitable. Despite these reservations, which indi-
cate that only a relatively small proportion of
antibiotic prescribing may have been available for
further rationalisation, this report went on to
suggest a number of measures to control and
reduce antibiotic prescribing in the UK.
Following on from this initiative were further
reports, action plans and campaigns to reduce
antibiotic prescribing (Table 1). However, none of
these sought to address the impact of changes in
antibiotic prescribing on patient outcomes. In
addition, no speciﬁc studies were planned to
examine the success of these interventions in
reducing antibiotic resistance. However, as a
consequence of these initiatives, antibiotic pre-
scribing in England decreased by c. 23% overall,
from a peak level of 44.5 million prescriptions in
1995 ⁄ 96 to 34.2 million prescriptions in 1999 ⁄ 2000
[21].
The impact of these substantial changes in
antibiotic prescribing for lower respiratory tract
infection on outcomes in community-acquired
pneumonia were investigated in a retrospective
analysis of pneumonia mortality [22]. Antibiotic
prescriptions for lower respiratory tract infection
showed a 30% decline from 42.3 ⁄ 1000 in 1995 ⁄ 96
to 29.6 ⁄ 1000 in 1999 ⁄ 2000, whereas winter pneu-
monia mortality, corrected for inﬂuenza inci-
dence, increased from 20.4 deaths ⁄ 100 000 in
1995 ⁄ 96 to 30.7 deaths ⁄ 100 000 in 1999 ⁄ 2000
(Fig. 1) [22]. This represented an increase of
50.6% in pneumonia excess mortality. Using
negative binomial regression, when inﬂuenza
and antibiotic prescribing were both included in
the model, there was a signiﬁcant relationship
between the reduction in antibiotic prescribing in
lower respiratory tract infection and excess pneu-
monia mortality (p < 0.001).
Table 1. Initiatives in the UK that aimed to reduce antibiotic resistance, primarily by restricting antibiotic prescribing
March 1998 Resistance to Antibiotics and other Antimicrobial Agents: House of Lords Select Committee on Science and
Technology
September 1998 The Path of Least Resistance: Department of Health Standing Medical Advisory Committee Report
December 1998 Resistance to Antibiotics and other Antimicrobial Agents: Draft responses to House of Lords Report
1999 Local primary care contract prescribing incentives to cut speciﬁc therapeutic group age–sex
weightings related prescribing units for antibiotics by 10–15% over previous year
March 1999 Resistance to Antibiotics and other Antimicrobial Agents: Health Service Circular, Department of Health
Campaign on Antibiotic Treatment (CAT) in primary care
October 1999 National Advice to Public (NAP): Department of Health publicity campaign (‘Andy Biotic’)
2000 Local primary care contract prescribing incentives to cut speciﬁc therapeutic group age–sex
weightings related prescribing units for antibiotics by 10–15% over previous year
June 2000 UK antimicrobial resistance strategy and action paper. Department of Health year plan
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Fig. 1. Trends in antibiotic prescribing in lower respirat-
ory tract infection (LRTI) in England and Wales, and
winter excess pneumonia mortality corrected for inﬂuenza
incidence [22] (adapted with permission).
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A second longitudinal study conducted in
England showed that hospital admissions for
respiratory infection increased as total antibiotic
prescribing declined [23]. However, cross-
sectional population-based studies have shown a
more mixed picture. A comparison of health
authorities showed that increased penicillin use
was associated with a decreased risk of compli-
cations of common acute respiratory infections
[24], although an association between antibiotic
prescriptions and hospital admissions for respir-
atory tract infection was not conﬁrmed in a
comparison made at the level of primary care
trusts [23].
Studies conducted to date have a number of
limitations, the most important of which is that
the patients dying of pneumonia, or with compli-
cations, may have been prescribed antibiotics.
Studies of patient-level data are needed, therefore,
to determine whether delayed, inappropriate or
absent antibiotic prescribing is a risk factor for
pneumonia mortality. In addition, other outcome
measures may be more sensitive indicators of
optimal prescribing, such as hospitalisation and
duration of hospitalisation, outpatient visits, dur-
ation of antibiotic therapy and time to recovery.
The rate of pneumonia-associated bacteraemia
and whether this has changed with altering
antibiotic prescribing habits also remains to be
investigated.
A second important limitation is that the
evidence to date is solely from the UK. In fact,
in 1997, the UK was among those countries in
Europe with the lowest rates of antibiotic con-
sumption (Fig. 2). At that time, it also had a
relatively low prevalence of antimicrobial resist-
ance. It is possible that the UK may have already
contained prescribing to the point where resist-
ance was managed and positive outcomes max-
imised before the initiatives to restrict prescribing
began in 1998. In countries with higher levels of
antibiotic consumption, it may be that signiﬁcant
reductions in antibiotic prescribing in lower
respiratory tract infections could be achieved
without an adverse impact on outcomes, although
this has yet to be investigated. Thus, the broader
applicability of UK data to antibiotic prescribing
policy at a European and global level remains
open to question. Associations between antibiotic
prescribing and patient outcomes therefore need
to be investigated in a wider geographic context,
with data generated in a way that allows com-
parisons among different countries and ecological
situations.
IMPROVING DIAGNOSIS
As well as increasing our understanding of the
relationship between antibiotic prescribing and
patient outcomes in respiratory tract infection,
methods that achieve a more reliable diagnosis in
the primary care physician’s ofﬁce or that identify
patients that may be vulnerable to progression to
pneumonia need to be developed.
At present, differential diagnosis of commu-
nity-acquired pneumonia generally requires a
chest radiograph, which is not readily available
in the majority of primary care physician’s ofﬁces.
C-reactive protein levels have been suggested as a
diagnostic marker for pneumonia and as a meas-
ure of pneumonia severity, although data regard-
ing sensitivity, speciﬁcity and clinically relevant
cut-off values are conﬂicting [26–29]. However,
further work in this area may provide a useful
index of pneumonia risk and severity in the
future.
Microbiological testing can inform the diagno-
sis as bacterial and indicate pneumococcal
involvement, but is slow and not routine in
primary care, and does not differentiate bacterial
lower respiratory tract infection from bacterial
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Fig. 2. Outpatient sales of b-lactam and macrolide anti-
biotics in 1997 from 14 European countries [25].
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pneumonia. More recently, with the introduction
of the pneumococcal antigen test, a positive
ﬁnding may alert the physician to the increased
possibility of progression to a more serious
respiratory tract infection with this pathogen.
Investigations of rapid diagnostic methods for
pneumococcal disease are currently focused on
informing the decision as to whether to admit
patients to hospital. Testing is not yet routine in
primary care and the test should be regarded as
an augmentation to microbiological testing, with
the advantage of a rapid result [30]. However,
further evaluations of these tests, including in the
primary care setting, may provide a new oppor-
tunity to improve diagnosis and prescribing in
lower respiratory tract infection in a wider patient
population.
DISCUSSION
Changes in antibiotic prescribing for lower
respiratory tract infection may impact on patient
outcomes directly or indirectly. A direct effect
would occur if reductions in antibiotic prescri-
bing across the board for lower respiratory tract
infections are resulting in a proportion of
patients with community-acquired pneumonia
not receiving the antibiotic treatment that they
need in a timely fashion. Another direct effect
would be if prompt antibiotic treatment of lower
respiratory tract infection was preventing
patients from progressing to pneumonia. A
reduction in prescribing for lower respiratory
tract infection would therefore remove this
protective effect and increase the overall number
of pneumonias.
Indirect effects are based on changing patient
expectations. If patients have a repeated experi-
ence of being denied antibiotic therapy, despite
feeling signiﬁcantly unwell, they may fail to
present to the clinic when, in fact, their condition
warrants prompt antibiotic therapy. Just as it is
difﬁcult for doctors to diagnose bacterial infection
and to determine its severity and prognosis, it is
also difﬁcult for patients to differentiate between
their past experiences of ill health and the current
episode, and to judge whether they should make
an appointment with their primary care physi-
cian. Delaying this decision when antibiotic
therapy is needed could have signiﬁcant conse-
quences and result in late presentation of more
severe disease and an increased risk of mortality.
The difﬁculty is that we really do not know the
point at which additional beneﬁt from antibiotic
prescribing or additional risk of poor outcome
from antibiotic restriction is achieved. It cannot be
assumed that interventions to reduce prescribing
will not have unintended adverse consequences.
In addition, data from one country cannot neces-
sarily be extrapolated to another, because of
differences in factors such as climate, seasonality,
antibiotic resistance, healthcare systems and clin-
ical practice. It is important therefore that any
efforts to reduce antibiotic prescribing are accom-
panied by a rigourous investigation of their
impact on patient outcomes and bacterial resist-
ance, and that the risk:beneﬁt ratio of these
interventions is determined.
CONCLUSIONS
We have become dependent on antibiotics, but we
also need to address the increasing prevalences of
antibiotic resistance. We need to consider the
quality of prescribing, not just the frequency, and
use antibiotics appropriately to the best of our
knowledge. That does not mean restricting their
use according to cost, overall volume or how
recently they have been approved for use, but on
their efﬁcacy in meeting a medical need. Unfor-
tunately, deﬁning that medical need may not be
straightforward. In infections such as meningitis,
it is relatively clear-cut, but for many common
community-acquired infections, making a differ-
ential diagnosis of a bacterial infection, rather
than a viral infection or allergy, can be problem-
atic. If we undertreat bacterial infections, we may
risk an increased rate of complications and mor-
tality. In conclusion, when setting antibiotic poli-
cies, we need to consider that both overprescribing
that leads to resistance and underprescribing that
leads to poor outcomes can push us back towards
a situation that resembles the preantibiotic era.
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